JAG1 and B-cell chronic lymphocytic leukemia: Given the growing evidence that Notch signaling is activated in a large fraction of CLL patients23–25,33, and given this study showing that even Jag1 processing is a common event in CLL, the identification of novel therapeutic strategies targeting the Notch-ligand system in CLL may have important implications for improving the management of this disease.